Viewing Study NCT00141154



Ignite Creation Date: 2024-05-05 @ 11:50 AM
Last Modification Date: 2024-10-26 @ 9:14 AM
Study NCT ID: NCT00141154
Status: COMPLETED
Last Update Posted: 2021-03-03
First Post: 2005-08-30

Brief Title: Comparison Of Celecoxib 200 Mg Bid Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan
Sponsor: Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization: Pfizer

Study Overview

Official Title: A Randomized Multicenter Active And Placebo Controlled Parallel Group Study To Evaluate The Efficacy And Safety Of Celecoxib Ym177 200 Bid Compared To Loxoprofen 60 Mg Tid In Patients With Low Back Pain
Status: COMPLETED
Status Verified Date: 2021-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To verify the superiority of celecoxib YM177 200 mg bid to placebo in treatment of patients with low back pain as well as non-inferiority to loxoprofen sodium 60 mg tid
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None